Original Article
Comparative Genomic Hybridization Analysis of Human Parathyroid Tumors

https://doi.org/10.1016/S0165-4608(98)00049-1Get rights and content

Abstract

Primary hyperparathyroidism is characterized by hypercalcemia and elevated parathyroid hormone levels. It can be caused by overactivity of one (adenoma or carcinoma) or more (hyperplasia or multiple adenoma) parathyroid glands. Parathyroid adenoma and hyperplasia are usually mono- or oligoclonal neoplasms. To establish whether parathyroid cancer has a genetic composition distinct from parathyroid adenoma, we analyzed 10 adenoma and 10 carcinoma cases by comparative genomic hybridization (CGH). Results show clear differences between the constitution of adenoma and carcinoma genomic DNA. The most frequent genomic alterations in adenoma included deletions on chromosomes 11, 17 (5 of 10 cases), and 22 (7 of 10 cases). In parathyroid carcinoma, frequent chromosomal deletions were on chromosome arm 1p (4 of 10 cases) and chromosome 17 (3 of 10 cases), and gains were on chromosome 5 (3 of 10 cases). Our data indicate that different genetic changes could contribute to the development of parathyroid adenoma and carcinoma; genomic losses predominate in adenoma, and gains along with some losses are found in carcinoma. Furthermore, the CGH results implicate several chromosomal regions that may harbor genes that could be potentially involved in the development of parathyroid adenoma and carcinoma. Published by Elsevier Science Inc.

Introduction

Primary hyperparathyroidism (pHPT) is a common endocrine disorder characterized by dysregulation and excessive secretion of parathyroid hormone (PTH) from one or more parathyroid glands. PTH excess may be produced by a parathyroid adenoma, parathyroid hyperplasia, or a parathyroid carcinoma. The chief biochemical manifestation of primary PTH excess is hypercalcemia. Approximately 100,000 new cases of pHPT per year are estimated in the United States [1]. Most patients with pHPT (80–85%) harbor a single adenoma; the other three glands are normal. About 15–20% of the patients with pHPT have hyperplasia that involves enlargement of all four parathyroid glands occurring sporadically or in conjunction with an inherited disorder such as multiple endocrine neoplasia (MEN) type 1 or 2. The rarest form of pHPT is parathyroid carcinoma with a single gland enlarged; this form is seen in well under 1% of all patients with pHPT [2]. The parathyroid adenoma is a solitary hyperfunctional benign monoclonal parathyroid tumor [1]. The carcinoma shows unrestrained growth, is often palpable, and usually presents with severe hypercalcemia. Additionally, the carcinoma tends to be locally invasive and has the ability to metastasize. Not enough evidence exists to show that parathyroid cancer usually arises from an adenoma.

Tumor cytogenetic analysis has so far not indicated the involvement of chromosomal target regions that could be intensively searched for direct-acting oncogenes or tumor-suppressor genes causing parathyroid lesions. A translocation between chromosomes 1 and 5 has been reported in a single parathyroid adenoma [3], but it is unclear whether this was an isolated random occurrence or will be characteristic of a distinct subset of adenomas. The cyclin D1 (PRAD1) oncogene is rearranged with the PTH gene and is thereby transcriptionally activated in a very small subset of parathyroid adenoma 4, 5. Loss of heterozygosity (LOH) analyses in parathyroid adenoma have detected allelic loss of chromosome 11q in 35–40%, LOH on chromosome arms 1p, 6q, 11p, and 15q in 30%, and allelic loss of 3q markers in 10% of cases 6, 7, 8, 9, 10, 11. Allelic loss of the retinoblastoma tumor-suppressor gene reported to be highly specific for parathyroid carcinoma 12, 13 also has been detected in 16% of parathyroid adenomas associated with aggressive clinical and histopathological features [14]. Allelic loss of the p53 tumor-suppressor gene was observed in parathyroid carcinoma from 2 of 6 genetically informative patients and not in parathyroid adenoma from 20 informative patients [15]. Analysis of gene amplification has not been reported in parathyroid cancer or adenoma. Analysis of both gains and losses of chromosomal regions is possible with comparative genomic hybridization (CGH), first described by Kallioniemi et al. [16]. We have used CGH to screen 10 frozen parathyroid adenoma samples, 1 frozen parathyroid carcinoma, and 9 paraffin-embedded parathyroid carcinoma samples.

Section snippets

Tissue Samples

Parathyroid adenoma samples were obtained from patients undergoing parathyroidectomy for the management of primary hyperparathyroidism at NIH. Patients exhibited accepted clinical features of sporadic parathyroid adenoma. No patient had MEN1 or a history of neck irradiation. All were hypercalcemic with elevated levels of parathyroid hormone. None of the adenomas had clinicopathological features of malignancy. After surgical removal, tissue was immediately frozen in liquid nitrogen and then

Results

We used CGH to identify DNA sequence copy number changes in 10 parathyroid adenomas and 10 parathyroid carcinomas.

Discussion

We performed CGH analysis of single gland parathyroid tumors, adenoma and parathyroid carcinoma, in an effort to scan the entire tumor genome for DNA sequence copy number changes. CGH has the power to perform a genomewide analysis of both loss and gain of chromosomal regions that may harbor genes involved in the pathogenesis of different tumors. Not much data are available for parathyroid carcinoma owing to the lack of sufficient amount and preservation of tissue. CGH analysis is possible in

Addendum

During the review process of the present investigation, a study describing CGH analysis of parathyroid adenomas was also published in J Clin Endocrinol Metab 83:1766–1770 (1998).

Acknowledgements

We thank Tim Veldman for assistance in chromosome identification.

References (42)

  • H. Iwasaki

    A possible tumor suppressor gene for parathyroid adenomas

    Int Surg

    (1996)
  • H. Tahara et al.

    Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas

    Cancer Res

    (1996)
  • D.B. Thompson et al.

    Genetic abnormalities in sporadic parathyroid adenomasloss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus

    J Clin Endocrinol Metab

    (1995)
  • V.L. Cryns et al.

    Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma

    N Engl J Med

    (1994)
  • C. Dotzenrath et al.

    Allelic loss of the retinoblastoma tumor-suppressor genea marker for aggressive parathyroid tumors

    J Clin Endocrinol Metab

    (1996)
  • S.H.S. Pearce et al.

    Loss of heterozygosity studies at the retinoblastoma and breast-cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid-tumors

    Clin Endocrinol

    (1996)
  • V.L. Cryns et al.

    P53 abnormalities in human parathyroid carcinoma

    J Clin Endocrinol Metab

    (1994)
  • A. Kallioniemi et al.

    Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors

    Science

    (1992)
  • T. Ried et al.

    Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas

    Cancer Res

    (1995)
  • J. Sambrook et al.

    Molecular CloningA Laboratory Manual

    (1989)
  • R.S. Verma et al.

    Human ChromosomesPrinciples and Techniques

    (1995)
  • Cited by (83)

    • Thyroid and Parathyroid Glands

      2020, Gnepp's Diagnostic Surgical Pathology of the Head and Neck, Third Edition
    • Hyperparathyroidism

      2018, Genetics of Bone Biology and Skeletal Disease: Second Edition
    • Genetics of Hyperparathyroidism, Including Parathyroid Cancer

      2017, Endocrinology and Metabolism Clinics of North America
    • Diagnostic Pathology: Head & Neck

      2017, Diagnostic Pathology: Head and Neck
    View all citing articles on Scopus
    View full text